The NDRG2 (N-Myc downstream-regulated gene 2) antibody is a key tool for studying the NDRG2 protein, a member of the NDRG family involved in cellular processes like differentiation, stress response, and tumor suppression. NDRG2 is ubiquitously expressed, with high levels in the brain, kidney, and skeletal muscle. It functions as a tumor suppressor by regulating pathways such as HIF-1α, p53. and NF-κB, and is implicated in cancers (e.g., glioblastoma, colorectal cancer), neurodegenerative diseases, and metabolic disorders. Antibodies targeting NDRG2 enable researchers to detect its expression, localization, and interactions in tissues or cell lines via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Validated antibodies are critical for ensuring specificity, often confirmed using knockout (KO) controls. Commercial NDRG2 antibodies vary by host (e.g., rabbit, mouse), clonality (monoclonal/polyoclonal), and applications (e.g., paraffin-embedded vs. frozen sections). Their development has advanced studies on NDRG2's role in hypoxia response, neuronal survival, and cancer metastasis. However, discrepancies in antibody performance across experimental conditions highlight the need for rigorous validation. Research using these antibodies continues to explore NDRG2 as a diagnostic biomarker or therapeutic target in diseases linked to cellular stress and proliferation.